Mean change in BCVA from baseline to month 6 for the entire cohort was 5.2 letters. Subgroup analyses indicated that the improvement was driven by gains in the treatment-naïve arm that had an average gain of 8.5 letters compared with just 1.1 letters in the previously treated patients.
Mean CRT for the entire group decreased from 447 µm at baseline to 348 µm at 6 months.
“The trajectories of anatomic improvement were similar in the 2 study subgroups with all patients demonstrating anatomic improvement with suprachoroidal CLS-TA delivery,” Dr. Wykoff said. “At the end of 6 months, 89% of patients achieved a >50% reduction in excess CRT.”
Mean IOP was relatively stable across the 6-month trial with a slight increase of 1 mm Hg to 2.5 mm Hg seen at months 4 and 5. Two patients (10%), both in the previously treated arm experienced an IOP increase >10 mm Hg, and 15% of patients were started on topical IOP-lowering medication.